Skip to main content

Table 1 Key model inputs

From: Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation

  Mean Distribution 95% confidence interval
Cost parameters
 Multimodal screening (drop-outs) £54 Beta £33 to £74
 Multimodal screening (complete screening) £61 Hybrida £37 to £83
 Ultrasound screening (drop-outs) £56 Gamma £29 to £92
 Ultrasound screening (complete screening) £61 Hybrida £31 to £100
 Screening invitation (either strategy) £2.09 Gamma £1.70 to £2.52
 Diagnosis: Borderline £110 Gamma £91 to £135
 Diagnosis: Stage 1 ovarian cancer £116 Gamma £90 to £133
 Diagnosis: Stage 2 ovarian cancer £126 Gamma £94 to £140
 Diagnosis: Stage 3 ovarian cancer £126 Gamma £102 to £152
 Diagnosis: Stage 4 ovarian cancer £112 Gamma £102 to £152
 Treatment: Borderline £3000 Gamma £1161 to £5696
 Treatment: Stage 1 ovarian cancer £6961 Gamma £4856 to £9438
 Treatment: Stage 2 ovarian cancer £7325 Gamma £5211 to £9795
 Treatment: Stage 3 ovarian cancer £9016 Gamma £6866 to £11,454
 Treatment: Stage 4 ovarian cancer £5892 Gamma £3823 to £8402
 End of life cost: ovarian cancer £7080 Gamma £5761 to £8533
Utility parameters
 Utility cancer free 0. 900 Beta 0.325 to 1
 Disutility Stage 1 ovarian cancer or false positive result 0.200 Beta 0.044 to 0.437
 Disutility Stage 2 ovarian cancer 0.325 Beta 0.214 to 0.534
 Disutility Stage 3 ovarian cancer 0.413 Beta 0.329 to 0.600
 Disutility Stage 4 ovarian cancer 0. 455 Beta 0.413 to 0.601
Number of false positives per cancer identified
 Multimodal screening 2.302 Beta 2.188 to 2.412
 Ultrasound screening 9.963 Beta 9.813 to 10.104
  1. aMixture of gamma and beta distributions; see Additional file 1 for more details